1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ImmuPharma PLC

ImmuPharma PLC

IMM.L
ImmuPharma PLCGB flagLondon Stock Exchange
3.75
GBp
+0.27
- -
16.88MMarket Cap
ImmuPharma PLC
IMM.L
(London Stock Exchange)

Recent

price

3.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-0.04
-0.05
-0.05
-0.03
-0.04
-0.05
-0.05
-0.05
-0.04
-0.03
-0.03
-0.01
-0.01
-0.01
- -
Basic EPS, GAAP
-0.09
-0.04
-0.04
-0.05
-0.03
-0.05
-0.06
-0.03
-0.03
-0.03
-0.02
-0.02
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.14
0.1
0.06
0.01
-0.01
-0.06
-0.06
-0.09
-0.14
-0.15
-0.1
-0.11
-0.11
-0.09
-0.09
- -
Book Value per Share
0.19
0.15
0.1
0.06
0.06
0.01
0.04
0.02
0.05
0.03
0.05
0.02
0.01
- -
- -
- -
Tangible Book Value per Share
81
82
82
82
84
89
117
131
139
153
200
251
303
362
416
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-18,362.5
-22,770.21
- -
- -
-1,853.15
-5,972.11
-3,998.67
-4,807.88
-9,941.04
-8,061.14
-4,412.7
-4,359.84
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-3
-4
-4
-3
-4
-5
-6
-7
-6
-7
-8
-4
-3
-2
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-6,181.25
-19,916.78
- -
- -
-1,553.71
-5,100.97
-3,230.91
-4,136.06
-8,866.22
-7,858.31
-5,415.72
-6,906.55
- -
- -
- -
- -
Profit Margin (%)
16
13
9
5
5
1
5
3
5
3
6
2
1
- -
-1
1
Working Capital
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
16
13
8
5
6
2
6
4
8
5
10
4
3
1
-1
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-15.63
-33.32
-59.41
-133.16
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-17.5%
-106.64%
-226.53%
Free Cash Flow
0.97%
0.41%
34.07%
Net Income, GAAP
-3.35%
-19.95%
-27.21%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Fluicell AB (publ) (FLUI.ST)
Oxurion N.V. (OXUR.BR)
Shandong Boan Biotechnology Co., Ltd. (6955.HK)
Cybin Inc. (CYBN)
Ensysce Biosciences, Inc. (ENSC)
AbCellera Biologics Inc. (ABCL)
Business
ImmuPharma PLC is a specialist biopharmaceutical company focused on the discovery and development of peptide-based therapeutics targeting autoimmune diseases, inflammation, anti-infectives and oncology; its lead product, P140 (formerly Lupuzor and forigerimod), comprises a first-in-class autophagy immunomodulator in late-stage development for systemic lupus erythematosus and chronic inflammatory demyelinating polyneuropathy, complemented by a next-generation companion diagnostic for precision patient identification and monitoring; the pipeline also features BioAMB, an improved peptide formulation of amphotericin-B addressing systemic antifungal limitations, and BioCin, an enhanced vancomycin analog effective against methicillin-resistant Staphylococcus aureus and Clostridium difficile infections. Founded in 1999 and headquartered in London, England, with research operations primarily in France including collaborations with CNRS, the company operates across the UK, Euronext Growth Brussels and targets global markets for high-unmet-need conditions characterized by immune dysregulation and resistant infections. Recent developments include the filing of a new P140 patent in September 2025 extending potential protection to 2045, the launch of a redesigned corporate website in October 2025 highlighting its autoimmune platform transformation, ongoing engagement with multiple potential commercial partners for P140 with deal completion now targeted for 2026 following positive due diligence responses, strengthened cash position into Q4 2026 from R&D tax credits, warrant exercises and enhanced Lanstead Capital receipts totaling approximately £2 million, alongside reaffirmation of no near-term fundraising needs.

Company News

APIChatGPT

  • defenseworld.net

    ImmuPharma (LON:IMM) Stock Price Crosses Below 200 Day Moving Average – Should You Sell?

  • defenseworld.net

    ImmuPharma (LON:IMM) Trading Up 0.9% – Should You Buy?

  • defenseworld.net

    ImmuPharma (LON:IMM) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened